Skip to Content

Consumer Health Privacy Notice

This Consumer Health Privacy Notice (“Notice”) is intended to supplement the Clinical Trial Media, Inc. Privacy Notice and other applicable privacy notices (“privacy statements”) to provide additional notices related to health information or health data (“health information”) as defined by Washington and Nevada law. Washington and Nevada require Clinical Trial Media, Inc. to provide you with additional information about how we may collect, use, disclose or otherwise process your health information, how we protect it, and your rights and choices with respect to your health information.

This Notice applies to all Clinical Trial Media, Inc. operations as well as websites, mobile applications and digital services (“Services”) that link to or post it.

Scope

Health information for purposes of this Notice has the definition given in Washington or Nevada law, including information that identifies or is reasonably capable of being associated or linked, directly or indirectly, with a particular consumer and that identifies the consumer’s past, present, or future physical or mental health status. This Notice applies only to residents of Washington and Nevada and individuals whose information is processed in Washington or Nevada.

This Notice does not apply to the personal information that we collect and process about Clinical Trial Media, Inc. workforce members, including job applicants; active and inactive Clinical Trial Media, Inc. employees; former employees; retirees; dependents; beneficiaries; employees of Clinical Trial Media, Inc.’s third-party vendors and partners, such as contractors on assignment at Clinical Trial Media, Inc.; and other individuals about whom Clinical Trial Media, Inc. collects PI for HR-related purposes. It does not apply to health information that is used to engage in public or peer-reviewed scientific, historical, or statistical research that adheres to all other applicable ethics and privacy laws.

In certain circumstances, we may collect or use your information through our Services while acting as a “business associate” under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), and your information may constitute “Protected Health Information.” This Notice does not apply to Protected Health Information or any health information processed in circumstances where Clinical Trial Media, Inc. is acting as a business associate under HIPAA.

Health Information Practices

Categories of Health Information

The categories of health information we collect will depend on how you interact with Clinical Trial Media, Inc. Services and the information you choose to provide. We may collect:

  • Health conditions, treatments, diseases, or diagnosis
  • Social, psychological, behavioral, and medical interventions
  • Health-related surgeries or procedures
  • Use or purchase of prescribed medication
  • Bodily functions, vital signs, symptoms, or measurements of other types of consumer health data
  • Diagnoses or diagnostic testing, treatment, or medication
  • Reproductive or sexual health information
  • Biometric data
  • Genetic data
  • Data that identifies a consumer seeking health care services
  • Other information that may be used to infer or derive data related to the above or other health information.

Purposes for Collection

With your consent, we may use the health information we collect for the following purposes, as further described in our privacy statements:

  • Providing Services and support. To provide and operate our Services; communicate with you about your use of our products and Services (e.g., through SMS/MMS and emails), including through the use of our AI tools that assist our support centers; fulfill product orders or requests for samples; provide troubleshooting and technical support; respond to your inquiries; gather customer feedback; fulfill your requests; process your payments; communicate with you; and for similar Service and support purposes.
  • Analytics and improvement. To better understand how users access and use our Services, products, and offerings, and for other research and analytical purposes, such as to evaluate and improve our Services and business operations, to develop Services and features, and for internal quality control and training purposes.
  • Customization and personalization. To tailor the content that we may send you and that we may display on the Services, including to offer personalized help and instructions, and to otherwise personalize your experience.
  • Marketing and advertising. For example, to send you information about our Services, such as marketing content, we think may interest you, as well as any other information that you sign up to receive. We also may use certain health information that we collect to manage and improve our advertising campaigns so that we can better reach individuals with relevant content.
  • Security and protection of rights. To protect our Services and our business operations; to prevent and detect fraud, unauthorized activities and access, and other misuse; where we believe necessary to investigate, prevent or take action regarding illegal activities, suspected fraud, situations involving potential threats to the safety or legal rights of any person or third party, or violations of our Privacy statements.
  • Legal proceedings and obligations. To comply with the law and our legal obligations, to respond to legal process and related legal proceedings.
  • General business and operational support. To consider and implement mergers, acquisitions, reorganizations, bankruptcies, and other business transactions, and related to the administration of our general business, accounting, auditing, compliance, recordkeeping, and legal functions.

Sources of Health Information

As described further in the Data We Collect About You section of the Privacy Notice, we collect personal data (which may include health information) directly from you, from your interactions with our products and Services, from third parties, and from publicly available sources:

  • We may collect additional information such as health information related to your interactions with our products and Services.
  • We may collect health information about you from third-party sources, such as public databases, joint marketing partners, social media platforms, government sources, or other third parties.

Clinical Trial Media, Inc. does not sell or share your health information with third parties. We may disclose health information to our processors for our business purposes or at your direction to provide you with products and Services that you request.

Your Rights and Choices

You have the following rights with respect to your health information:

  • The right to confirm whether we are collecting, selling or sharing your health information
  • The right to withdraw consent for us to collect or share your health information
  • The right to request that we delete your health information
  • The right to correct your health information

There may be certain exceptions that apply to your request. To exercise your rights, you or your authorized representative may submit a request to privacy@clinicaltrialmedia.com. You may be entitled, in accordance with applicable law, to appeal a refusal to take action on your request. To do so, please contact us by using one of the methods listed in the Contact Details section in our privacy statements. You will not be discriminated against for exercising any of your rights.

We may update this Consumer Health Privacy Notice from time to time. When we do update it, for your convenience, we will make the updated statement available on this page. We will always handle your health information in accordance with this Notice in effect at the time it was collected unless we provide you with the new notice and/or obtain your consent or authorization, as appropriate.

Let’s discover what’s possible together.

ESTÁ SALIENDO DE ESTE SITIO WEB

Está saliendo de lillyadresearch.com/es-us/ y se le redirigirá a un sitio web que no es operado por Clinical Trial Media, Inc. Tenga en cuenta que Clinical Trial Media, Inc. no es responsable por el contenido ni la disponibilidad de este sitio web, y que sus políticas de privacidad y seguridad podrían ser diferentes de las de nuestro sitio web.

ESTÁ SALIENDO DE ESTE SITIO WEB

Está saliendo de lillyadresearch.com/es-us/ y se le redirigirá a un sitio web que no es operado por Clinical Trial Media, Inc. Tenga en cuenta que Clinical Trial Media, Inc. no es responsable por el contenido ni la disponibilidad de este sitio web, y que sus políticas de privacidad y seguridad podrían ser diferentes de las de nuestro sitio web.

Estos son los objetivos que guían el trabajo de Lilly:

Crear una estrategia sólida para los estudios de investigación clínica y llegar a poblaciones diversas:

Nuestros equipos buscan que los participantes de cada estudio reflejen la composición de la población de pacientes que podrían usar el medicamento del estudio si se lo aprueba. En los distintos estudios de todo el mundo, identificamos y abordamos los obstáculos que impiden la participación de ciertas poblaciones que normalmente tienen una representación menor.

Seleccionar intencionalmente un rango diverso de centros e investigadores:

Buscamos incorporar más investigadores y asesores externos que representen a las mujeres y las poblaciones de minorías raciales y étnicas en los estudios. Nuestro objetivo máximo es que en nuestros grupos de investigadores y asesores se refleje la composición de la población de pacientes en términos de género y raza u origen étnico.

Aumentar la representación diversa mediante asociaciones y colaboraciones:

Colaboramos con pacientes, grupos de representación de pacientes, agencias reguladoras, profesionales del cuidado de la salud y organizaciones de la comunidad para identificar e implementar soluciones que deriven en una representación diversa, que mejoren la igualdad en materia de salud y que generen pruebas para dar un mejor apoyo a los resultados de los pacientes.

Astrocitos y microglías

Mantener las neuronas en buen estado es importante para hacer cosas como moverse o para recordar cosas. Es aquí donde entran en juego los astrocitos y las microglías. Estas son células del cerebro que eliminan los desechos y protegen a las neuronas del daño físico y químico.

La enfermedad de Alzheimer distorsiona el equilibrio que mantiene a las neuronas en buen estado. Esto puede ocurrir una década o más antes de que la persona comience a tener síntomas.2

Beta amiloide y tau

La investigación sugiere que hay dos proteínas involucradas en los cambios que ocurren en el cerebro a causa de la enfermedad de Alzheimer: beta amiloide y tau.3 Por motivos que todavía se desconocen, estas proteínas se vuelven tóxicas y causan problemas en el cerebro.
  • La proteína beta amiloide se acumula en masas y forma placa. Estas placas de amiloide se acumulan entre las neuronas.
  • La proteína tau se acumula dentro de las neuronas y con el tiempo forma ovillos.
Mientras la placa de amiloide se acumula, la proteína tau se esparce rápidamente por el cerebro. Esto resulta demasiado para los astrocitos y las microglías. Como las microglías ya no pueden eliminar con eficiencia los desechos y los astrocitos quedan sometidos a situaciones de gran esfuerzo, se produce una inflamación crónica en el cerebro.4

Con el tiempo, las neuronas ya no pueden comunicarse y mueren.

Hipocampo

Cuando las neuronas mueren, el cerebro se encoge. El daño con frecuencia comienza en el hipocampo, que es responsable del aprendizaje y la memoria.2 Cuanto mayor sea la cantidad de neuronas que mueren, la persona que tiene enfermedad de Alzheimer menos podrá pensar, recordar, tomar decisiones o funcionar de manera independiente.4

Los estudios de investigación clínica están explorando opciones para detener o retrasar la aparición de problemas de memoria y pensamiento asociados a la enfermedad de Alzheimer. Si usted o un ser querido está afectado, la investigación clínica podría ofrecerles opciones.

Neuronas

Por ejemplo, consideremos qué sucede cuando mira esta imagen. Cuando miramos, gritamos, caminamos o recordamos, es el resultado de señales que se transmiten a través de los 100 000 millones de células nerviosas que tenemos en el cerebro, llamadas neuronas.

Estas neuronas se comunican entre sí mediante señales eléctricas. Estas señales pueden generar suficiente electricidad como para encender una bombilla de luz de bajo consumo.1 La combinación de estas señales eléctricas y químicas es responsable de las acciones que se mencionan anteriormente.

YOU ARE NOW LEAVING THIS WEBSITE

You are now leaving lillyADresearch.com and being redirected to a website that is not operated by Clinical Trial Media, Inc. Please be aware, Clinical Trial Media, Inc. is not responsible for the content or availability of this website and its privacy and security policies may differ from those on this website.

YOU ARE NOW LEAVING THIS WEBSITE

You are now leaving lillyADresearch.com and being redirected to a website that is not operated by Clinical Trial Media, Inc. Please be aware, Clinical Trial Media, Inc. is not responsible for the content or availability of this website and its privacy and security policies may differ from those on this website.

Neurons

See how you’re staring at this image? When we stare, shout, walk, or remember, it’s the result of signals passing through the 100 billion nerve cells in our brain called neurons.

Electrical charges help these neurons talk to each other. These charges can generate enough electricity to power a low-wattage bulb!1 The combination of these electrical and chemical signals is responsible for the actions mentioned above.

Hippocampus

As neurons die, the brain shrinks. The damage often starts in the hippocampus, which is responsible for learning and memory.2 The more neurons die, the less a person with Alzheimer’s disease is able to think, remember, make decisions, or function independently.4

Clinical research studies are exploring ways to stop or slow down the appearance of memory and thinking problems associated with Alzheimer’s disease. If you or a loved one is affected, there may be options through clinical research.

Beta-Amyloid and Tau

Research suggests that two proteins are involved in driving changes to the brain due to Alzheimer’s disease: beta-amyloid and tau.3 For reasons still unknown, these proteins become toxic and cause problems in the brain.
  • Beta-amyloid clumps together to form plaque. These amyloid plaques build up between neurons.
  • Tau accumulates inside neurons and eventually forms tangles.
As amyloid plaque builds up, tau spreads rapidly through the brain. It’s too much for astrocytes and microglia to deal with. Because microglia are no longer able to keep up with clearing debris and astrocytes become stressed, chronic inflammation occurs within the brain.4

Eventually, neurons can no longer communicate, and they die.

Astrocytes and Microglia

Keeping the neurons healthy is important to do things like move or remember things. This is where astrocytes and microglia come in. These are cells in the brain that clear away debris and protect neurons from physical or chemical damage.

Alzheimer’s disease disrupts the balance that keeps neurons healthy. This may happen a decade or more before a person starts to show symptoms.2

These goals guide Lilly’s work:

Create a Robust Clinical Research Study Strategy and Reach Diverse Populations

Our teams aim for each study’s participants to match the composition of the patient population that might use that study’s medicine if it’s approved. Across research studies globally, we identify and address barriers that keep underrepresented populations from participating.

Intentionally Select a Diverse Range of Sites and Investigators

We aim to recruit more research study investigators and external advisors who represent women and racial/ethnic minority populations, with the ultimate goal of having our investigators and advisors match the composition of the patient population in terms of gender and race/ethnicity.

Increase Diverse Representation through Partnerships and Collaborations

We collaborate with patients, patient advocacy groups, regulatory agencies, healthcare professionals, and community organizations to identify and implement solutions that will result in diverse representation, improve health equity, and generate evidence to support better patient results.